Risk Assessment Emerging Pathogens: How to Choose

By Dr. Zubair Khalid, DVM, MS, PhD · 2026-11-11

Risk assessment for emerging pathogens differs from routine microbiology because the hazard is incompletely characterized, so the method you choose must work with incomplete data. The core rule of thumb is this: match the precision of the method to the precision of the data you actually have. When you know little, use structured expert judgment or a semi-quantitative risk matrix. When you have dose-response, prevalence, and consumption or exposure data, use quantitative microbiological risk assessment. When the question is where a pathogen will spread, use spatial or mechanistic modeling. When the question is how to work safely with the agent in your own laboratory, use a procedure-based biosafety risk assessment.

This article walks through the main risk assessment emerging pathogens options, lays out the pros and cons of each in a side-by-side table, and shows how real laboratories combine them.

What Risk Assessment Means for Emerging Pathogens

A risk assessment is a structured answer to four questions: what can go wrong (hazard identification), how likely it is (exposure and likelihood characterization), how bad it would be (consequence characterization), and what the overall risk level is (risk estimation). For established pathogens, decades of literature feed each step. For emerging pathogens, one or more of those steps runs on thin evidence, which is why the choice of framework matters so much.

An emerging pathogen is any infectious agent that is newly recognized, newly introduced to a population or region, or expanding in incidence or range. Hendra and Nipah viruses are textbook examples. They are zoonotic henipaviruses that spill over from bat reservoirs, amplify in domestic animals, and cause outbreaks with high case fatality rates, and their handling requires evidence-based containment decisions tailored to the specific pathogen, activity, and setting [1].

Two distinct risk questions run in parallel in any microbiology setting and they are often confused:

1. Public or animal health risk. Will this pathogen cause disease in people, livestock, wildlife, or food systems, and how should surveillance respond?
2. Laboratory biosafety risk. Could this pathogen infect the staff handling it, and what containment and practices are required?

Both fall under the umbrella of biosafety risk assessment, but they use different tools. Mixing them up is the single most common error in this field.

The Main Options, Explained on Their Own Terms

Option 1: Structured Expert Judgment and Participatory Assessment

When surveillance data are sparse, structured expert opinion is a legitimate primary method, not a fallback. The key word is structured. In a recent One Health application in Cameroon, experts on Ebola virus disease and Rift Valley fever were queried through semi-structured interviews and a monthly risk calendar, producing a semi-quantitative, context-refined picture of perceived high-risk periods and key risk factors where official epidemic records were absent [2].

The strengths are speed and feasibility. A facilitated workshop can produce a ranked risk profile in weeks, and the process builds shared situational awareness across human health, animal health, and environmental sectors. The weaknesses are equally clear: expert judgment inherits the biases of the expert panel, results are difficult to reproduce exactly, and perceived risk factors may diverge from measured ones. Structured protocols, defined scoring scales, and documented rationale reduce but never eliminate these problems.

Choose this option when the pathogen is genuinely novel in your region, when quantitative inputs do not exist, or when you need a fast, cross-sectoral consensus document to justify surveillance funding.

Option 2: Semi-Quantitative Risk Matrices for Laboratory Work

For day-to-day biosafety decisions, semi-quantitative matrices are the workhorse. A three-dimensional model developed for public health laboratories defines three core dimensions: pathogen hazard (H), laboratory activity type (A), and annual operation frequency mapped to likelihood of occurrence, combined in a single formula, R = H × A × L(F). Validation against real activity data from 16 district laboratories, covering 130 distinct pathogen tests, showed the matrix could sort activities into acceptable and unacceptable risk tiers and assign targeted control measures, with inactivated and non-infectious materials reaching 100 percent acceptable-risk classification [3].

This approach is attractive for primary-level laboratories because it is transparent, cheap, and auditable. Its main limitation is that it inherits whatever hazard scores you assign, so an emerging pathogen with an uncertain hazard rating can be scored confidently and incorrectly. Pair it with a formal review trigger whenever new virulence or transmissibility data appear.

Option 3: Procedure-Specific Biosafety Risk Assessment

Agent-based classification, which maps a Risk Group directly to a Biosafety Level, breaks down for emerging pathogens handled in modern laboratories with viral vectors, modified organisms, and multi-step protocols. The Procedure-Specific Risk (PSR) framework addresses this by making the exposure generated by the procedure, rather than the agent's taxonomy, the primary determinant of containment. It is an 8-step operational protocol that integrates agent Risk Group classification, procedural exposure characterization, and modulating factors into a Biosafety Level assignment matrix. Its components were derived from ten national and international biosafety reference documents, including the WHO Laboratory Biosafety Manual fourth edition, the US BMBL sixth edition, and the CDC Biological Risk Assessment guidance, and validation rested on content validity and convergent validity against those sources [4].

The practical advantage is reproducibility. Two assessors applying the same protocol to the same protocol steps should reach the same containment decision, which is exactly what interlaboratory consistency reviews need. The cost is process discipline. An 8-step assessment takes longer than pulling a Risk Group number from a table, and staff need structured microbiology biosafety training to apply it consistently.

Option 4: Quantitative Microbiological Risk Assessment (QMRA)

QMRA puts numbers on the whole chain: prevalence in the source, concentration, dose-response, and exposure frequency, ending in a probability of illness per exposure. It is the most defensible output when a decision carries regulatory or legal weight, and it is the only option that produces an absolute illness estimate.

A quantitative risk assessment of methicillin-resistant Staphylococcus aureus in raw and cooked chicken meat illustrates the approach end to end. Out of 200 samples, 26 percent carried S. aureus, 41.67 percent of 96 isolates were MRSA, and 5.2 percent showed vancomycin resistance. Enterotoxin genes sea and seb were present in 47.92 and 28.13 percent of isolates respectively, and 83.33 percent formed biofilm. The quantitative model concluded a non-negligible probability of illness from consumption [5].

The pros of QMRA are precision, sensitivity analysis, and the ability to test interventions in silico before spending money on them. The cons are data hunger and modeling effort. Every input needs a distribution, not just a point value, and for emerging pathogens those distributions often come from surrogate organisms or poorly matched settings, which must be stated explicitly in the uncertainty analysis.

Option 5: Bibliometric and Index-Based Prioritization

When the question is which pathogens to prioritize among many, objective proxies can beat committee votes. One approach used the H-index, a bibliometric measure originally designed to quantify an individual researcher's cumulative impact, as a proxy for pathogen impact on human and animal health. Applied to European pathogens, it separated 57 pathogens appearing solely in the top 100 human or animal lists from 43 appearing in both, found that the majority of high-impact human pathogens were zoonotic or emerging, and showed limited evidence that the H-index reasonably proxies animal pathogen impact [6].

This method is fast, repeatable, and free of panel politics. Its blind spot is obvious: citation volume reflects research attention, which correlates with but does not equal true disease burden, and neglected pathogens of genuine concern can rank low simply because nobody studies them. Use it as a screening layer, not a final decision.

Option 6: Environmental Niche and Mechanistic Transmission Models

When the question is where and when a pathogen will emerge, two model families dominate, and they answer the question differently. Environmental niche models, such as Maxent, correlate recorded occurrences with long-term bioclimatic variables to map climatic suitability. Mechanistic epidemiological models, such as a susceptible-exposed-infected-removed (SEIR) framework, simulate transmission directly, driven here by daily mean temperature to calculate the basic reproduction number R0, the average number of secondary infections caused by one infected individual in a fully susceptible population.

For Usutu virus, a mosquito-borne flavivirus expanding across Europe, a parallel implementation of both approaches on the same surveillance data produced convergent high-risk zones in parts of France, the Pannonian Basin, and northern Italy, but also diverging outputs elsewhere, demonstrating that the choice of algorithm materially changes the risk map [7]. The lesson for anyone choosing among risk assessment emerging pathogens options is that model structure is itself a risk factor. Where feasible, run both a correlative and a mechanistic model and treat agreement as confidence and disagreement as a flagged uncertainty.

Option 7: Risk-Tiered Detection Frameworks

A risk assessment is only as good as the detection data feeding it, and detection technology choice is itself a risk decision. A synthesis of the viable but non-culturable (VBNC) problem, in which major foodborne pathogens including E. coli O157:H7, Salmonella enterica, Listeria monocytogenes, and Campylobacter jejuni enter a metabolically active, virulent dormancy that evades culture-based detection, produced an evidence-based risk-tiered framework matching technology to operational objective [8].

The framework assigns:

• Tier 1, rapid point-of-need screening: PMAxx-RPA-LFA, approximately 50 to 60 minutes total, for on-site decision-making.
• Tier 2, regulatory confirmation and absolute quantification: PMA-dPCR.
• Tier 3, research and outbreak investigation: AI-enhanced hyperspectral microscopy or targeted metatranscriptomics.
• Integrated platforms: microfluidic phage-CRISPR-AI systems for continuous monitoring.

This tiering logic, matching operational objective to technology capability, generalizes beyond food safety. The same structure appears in aquaculture biosafety reviews, where environmental DNA and environmental RNA monitoring, biosensors, smart sensors, and microfluidic platforms are evaluated as tools for earlier detection and improved risk assessment alongside conventional water treatment [9]. The VBNC case also exposes a systematic assessment gap: because dormant but viable cells are invisible to standard culture, routine negative results can mask a real exposure pathway, and unexplained outbreaks may trace back to this blind spot [8].

Option 8: Integrated Frameworks for Resistance and Gene Mobility

Emergence is not limited to new species. Antimicrobial resistance genes and virulence determinants move between bacteria, and bacteriophages are the principal vehicles of that movement through transduction. A framework review for food safety found a striking asymmetry in current microbiological risk assessment: phage biocontrol agents enter quantitative models as a simple log-reduction term, while phage-mediated gene mobility is rarely represented explicitly, even though the discovery of lateral transduction, which mobilizes chromosomal regions at frequencies orders of magnitude above classical generalised transduction, suggests this transfer is routine rather than rare [10]. An assessment of an emerging pathogen that ignores horizontal gene transfer will systematically underestimate its evolutionary risk.

Side-by-Side Comparison

How to Choose: The Criteria That Decide Real Cases

Four questions resolve most choices.

First, what decision will the assessment support? A containment decision inside your laboratory needs the procedure-specific approach. A regulatory limit needs QMRA. A budget request for surveillance needs prioritization and expert consensus. Writing down the decision before choosing the method prevents the common failure of running an elaborate analysis that answers nobody's actual question.

Second, what data exist? If dose-response data for the agent are absent, QMRA on that agent is a modeling exercise dressed as measurement, and a structured expert or semi-quantitative approach honestly represents the evidence state. If georeferenced occurrence data exist but no transmission parameters, a niche model is available now while a mechanistic model waits on data [7].

Third, how reproducible must the result be? If two assessors might independently review the work, as in regulatory or accreditation contexts, structured protocols with matrices and templates outperform free-form expert judgment [4].

Fourth, what is the detection backbone? Every assessment downstream of testing inherits the sensitivity and blind spots of the assay. If your target can enter a non-culturable state under the stresses in your sample pathway, culture-based results will systematically understate risk, and a viability-aware tiered approach is warranted [8].

Worked Scenarios

Scenario 1: A Novel Zoonotic Virus Appears in a Neighboring Region

Your diagnostic laboratory may receive samples within weeks. You have no local data, high stakes, and a decision to make about containment and testing capacity. The right starting combination is structured expert judgment to define plausible exposure scenarios and risk periods, paired immediately with a procedure-specific biosafety assessment of every planned protocol step, from inactivation to molecular extraction. For henipavirus-class agents, the literature shows that risk-based containment under the WHO Laboratory Biosafety Manual fourth edition framework must be tailored to the specific activity, because occupational exposure risks differ sharply between field veterinarians, healthcare workers, and laboratory personnel, and validated inactivation and decontamination practices form a core part of the evidence base [1]. A semi-quantitative matrix such as R = H × A × L[F] can then rank which of your routine activities actually require upgraded containment, avoiding a blanket, resource-draining escalation [3].

Scenario 2: A Food Matrix With a Culture Blind Spot

You are responsible for release testing in a facility processing foods that undergo stress treatments known to induce the viable but non-culturable state in Listeria monocytogenes and Salmonella. Your culture results have been consistently negative, yet the commodity has outbreak history. Here the detection tier is the decision. A risk-tiered framework would place PMAxx-RPA-LFA at Tier 1 for rapid point-of-need screening in about 50 to 60 minutes, and reserve PMA-dPCR for Tier 2 regulatory confirmation and absolute quantification, escalating to targeted metatranscriptomics or hyperspectral approaches for outbreak investigation [8]. If your process also uses phage-based biocontrol, extend the assessment to ask whether transduction could move resistance or virulence genes in your product ecosystem, because current frameworks handle biocontrol and gene mobility asymmetrically [10].

Scenario 3: Mapping Where an Arbovirus Might Establish

Your public health agency needs a map to position mosquito surveillance. You have multi-year surveillance records of positive birds and standard climate datasets. Run the two model families in parallel. A Maxent environmental niche model trained on long-term bioclimatic variables gives you a suitability map quickly, while an SEIR model driven by daily mean temperature gives you R0-based transmission potential. For Usutu virus in Europe, both models converged on high-risk zones in parts of France, the Pannonian Basin, and northern Italy, and the convergence itself strengthened the confidence in those zones, while divergence elsewhere flagged areas needing better data [7]. Deliver both maps with an explicit statement of where they agree and disagree, rather than presenting either alone as definitive.

Building the Assessment: A Practical Sequence

A defensible biosafety risk assessment for an emerging pathogen in a working laboratory follows a consistent sequence, drawn from the convergent themes in modern frameworks [4][3][1]:

1. Define the agent and its Risk Group. Use the best available evidence, and flag where the classification rests on surrogate data.
2. Inventory every procedure. List each step from specimen receipt through disposal, including centrifugation, sonication, homogenization, and instrument maintenance.
3. Characterize exposure per procedure. Identify aerosol generation, sharps use, volume handled, and concentration state.
4. Score hazard, activity, and frequency. In the three-dimensional model this becomes R = H × A × L(F), which maps directly onto a hierarchical risk matrix [3].
5. Apply modulating factors. Staff competency, immunization, facility condition, and workload intensity all shift residual risk. Utilization data can vary widely across similar laboratories, which changes the risk profile of the same written procedure [3].
6. Assign containment and controls. Use the PSR logic so that the procedure, not just the agent, drives the Biosafety Level decision [4].
7. Document and validate. Anchor each component to recognized reference documents, as the PSR framework did against the WHO LBM4, BMBL sixth edition, and CDC Biological Risk Assessment guidance [4].
8. Define reassessment triggers. New pathogenicity data, a protocol change, an exposure incident, or new inactivation evidence restarts the loop.

The Role of Microbiology Biosafety Training

Every framework above depends on the assessor and the bench staff. Structured microbiology biosafety training is what converts a paper framework into consistent practice, and its role is visible in each option. The PSR framework explicitly requires procedural exposure characterization, a skill that only trained staff apply reliably [4]. The three-dimensional matrix validated in district laboratories assumed that activity types and frequencies were recorded accurately at the bench [3]. For high-consequence agents, evidence reviews for Hendra and Nipah viruses emphasize that effective management requires coordinated competence across human, veterinary, and laboratory domains within a One Health framework, including recognition of occupational exposure scenarios specific to each role [1].

Training programs should cover, at minimum, hazard identification, route-of-exposure reasoning, procedure-level risk scoring, correct selection and verification of inactivation and decontamination methods, incident reporting, and when to escalate a risk decision rather than resolve it locally. Training is not a one-time event. Reassessment triggers in the framework should be paired with refresher training triggers, and competency should be reverified after any protocol change.

Where Integrated Risk Thinking Is Heading

Across food, water, and agriculture, the trend is toward frameworks that integrate microbial and chemical risks rather than assessing them in silos. A comprehensive comparison of electrochemical versus free chlorine disinfection of secondary effluent built a comparative framework based on effective chlorine equivalent dose, showing that electrochemical disinfection achieved more efficient and more readily monitored inactivation of endogenous microbial indicators and pathogens, and that although it produced a higher total concentration of disinfection by-products, the overall toxicity assessed by computational and experimental methods was comparable to or lower than free chlorine, with an electrode inversion strategy reducing by-product formation further [11]. The methodological lesson for microbial risk assessment is that a fair comparison requires a common dose basis and a joint accounting of microbial and chemical endpoints.

The same integration appears in aquaculture, where an assessment framework links water quality, microbial ecology, pathogen surveillance, antimicrobial resistance, and preventive interventions, and positions emerging tools such as eDNA and eRNA monitoring, biosensors, and microfluidic platforms within biosafety decision-making rather than treating them as laboratory curiosities [9]. In food drying, a review of dehydrated products challenged the assumption of intrinsic safety, profiled the pathogens associated with these matrices, and evaluated synergistic protocols in which physical sterilization coupled with precision drying achieved 2.3 to 4.7 log reductions, arguing for interdisciplinary collaboration rather than single-technology fixes [12].

One Health risk accounting also extends into residues and resistance. A study of raw bovine milk in Lebanon quantified antibiotic residues by LC-MS-MS, found 15 percent of 200 samples contaminated with four major antibiotics, showed estimated daily intake within acceptable daily intake thresholds and a hazard quotient below 1 across age groups, and framed the entire evaluation through a One Health lens connecting veterinary drug use, residue exposure, and resistant organism carriage [13]. The structural takeaway is that emerging risk rarely arrives alone. An emerging pathogen assessment that ignores co-traveling chemical or resistance hazards will undercount total risk.

Common Mistakes and Limitations

Mapping Risk Group directly to Biosafety Level. Agent taxonomy alone does not capture procedural exposure. A low-Risk-Group agent handled in high-volume aerosol-generating steps can exceed the risk of a higher-Risk-Group agent handled in sealed inactivated workflows. Procedure-based assignment corrects this [4].

Trusting negative cultures unconditionally. If the target organism can enter the viable but non-culturable state under your processing stresses, culture negativity is not evidence of absence. VBNC cells of E. coli O157:H7, Salmonella, Listeria, and Campylobacter remain metabolically active and virulent while invisible to standard plating [8].

Choosing one model and reporting its output as the answer. Correlative and mechanistic models of the same pathogen produced materially different risk maps in the Usutu virus comparison, so a single-model output carries the algorithm's assumptions as hidden baggage [7].

Treating expert opinion as measurement. Participatory, expert-based assessments are valuable where data are absent, but their outputs are perceptions, structured and semi-quantified. Label them as such and pair them with a plan to collect the data that would eventually replace them.

Ignoring gene mobility in resistance risk. Resistance emergence assessments that consider only vertical mutation under selection pressure miss transduction. Lateral transduction mobilizes large chromosomal regions at frequencies orders of magnitude above classical generalised transduction, which changes the expected rate of resistance spread in bacterial communities where temperate phages circulate [10].

Letting citation counts substitute for burden data. The H-index proxy ranked pathogens by research attention, and its authors themselves reported limited evidence for its validity as a proxy for animal pathogen impact. It screens, it does not decide.

Assuming hazard quotients below 1 settle the question. Hazard-based metrics capture the endpoint they were built for, such as non-carcinogenic inhalation risk from bioaerosol exposure estimated with hazard quotient and hazard index approaches [14], or residue exposure against an acceptable daily intake [13]. They do not capture endpoints outside their model, and they inherit every exposure assumption fed into them.

Skipping reassessment. Emerging pathogens change, and so does the evidence about them. An assessment valid at first isolation may be obsolete by the time transmissibility or resistance data arrive. Build reassessment triggers into the framework at the start, not after an incident.

One further limitation applies to every framework here. Individual cases, particularly clinical decisions about patient management or animal care, require the judgment of a qualified veterinarian or physician working with the actual case, and no risk assessment document substitutes for that.

Frequently Asked Questions

What is the difference between risk assessment and biosafety risk assessment?

Risk assessment answers whether a pathogen threatens health at a population or product level, while biosafety risk assessment answers whether staff could be exposed while handling it in a specific procedure. The first usually supports surveillance or regulatory decisions, the second supports containment and practice decisions, and both are needed for an emerging pathogen.

Which risk assessment approach is best for emerging pathogens?

There is no single best approach, because the right method depends on the decision, the available data, and the required reproducibility. Structured expert judgment and semi-quantitative matrices fit early, data-poor stages, quantitative microbiological risk assessment fits regulatory decisions once inputs exist, and procedure-specific frameworks fit laboratory containment decisions.

Can expert judgment alone justify a biosafety decision?

Structured expert judgment can support early decisions where no data exist, especially when documented with defined scales and rationale. For containment assignments, pair it with a procedure-specific framework so the decision is reproducible by a second assessor and anchored to recognized reference documents.

How does Biosafety Level assignment relate to risk assessment?

Biosafety Level assignment should be the output of the assessment, not its starting point. Modern procedure-specific frameworks make the exposure generated by each protocol step the primary determinant of containment, integrating agent Risk Group and modulating factors into the final assignment rather than mapping Risk Group to Biosafety Level directly.

How often should a risk assessment for an emerging pathogen be updated?

Update whenever a reassessment trigger fires: new pathogenicity, transmissibility, or resistance data, a protocol change, a change in workload or facility, or any exposure incident. Failing that, review on a defined schedule, because the evidence base for an emerging pathogen changes faster than for established agents.

What training do laboratory staff need for emerging pathogen work?

Staff need structured microbiology biosafety training covering hazard identification, route-of-exposure reasoning, procedure-level risk scoring, inactivation and decontamination method selection and verification, incident reporting, and escalation criteria. Competency should be reverified after protocol changes, and for high-consequence agents training should extend across the human, veterinary, and laboratory roles that share the risk.

Sources

1. Hendra and Nipah viruses: Biosafety evidence for risk-based containment, inactivation practices, and one health preparedness.
2. A participatory expert-based risk assessment to inform zoonotic disease surveillance in Cameroon: the case of Ebola virus disease and Rift Valley fever.
3. A semi-quantitative risk assessment of pathogenic microorganism laboratories in Beijing's CDCs based on a three-dimensional risk matrix model.
4. An 8-step procedure-specific risk framework enables reproducible biosafety level assignment beyond agent-based classification.
5. Risk Assessment of Methicillin- and Vancomycin-Resistant Staphylococcus aureus in Raw and Cooked Chicken Meat.
6. A quantitative prioritisation of human and domestic animal pathogens in Europe.
7. Evaluating the risk for Usutu virus circulation in Europe: comparison of environmental niche models and epidemiological models.
8. A risk-tiered framework for detecting viable but non-culturable foodborne pathogens: a critical synthesis from technology comparison to integrated solutions.
9. Assessment of water prophylaxis and biosafety in finfish aquaculture - current and emerging technologies.
10. Integrating bacteriophage-mediated gene mobility into microbiological risk assessment: A framework for food safety.
11. Comprehensive assessment of electrochemical disinfection for real secondary effluent: more efficient with reduced secondary chemical risk?
12. Microbiological safety of dehydrated foods: risk analysis, technology evaluation, and synergistic strategies for next-generation processing.
13. Prevalence and Antibiotic Resistance of Staphylococcus aureus and Escherichia coli Isolated from Bovine Raw Milk in Lebanon: A study on Antibiotic Usage, Antibiotic Residues, and Assessment of Human Health Risk Using the One Health Approach.
14. Inhalation exposure and non-carcinogenic risk assessment of bacterial and fungal bioaerosols among wastewater treatment plants workers.